Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

Inclusion criteria : * Adult male or female participants. * Documented diagnosis of IPF according to the current 2011 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/ American Latin Thoracic Association (ATS/ERS/JRS/ALAT) guidelines. * Signed written informed consent. Exclusion criteria: * Age less than or equal to 40 years. * IPF disease diagnosis greater than 5 years. * Forced vital capacity (FVC) less than (\<) 40 percent (%) of predicted value. * Carbon monoxide diffusing lung capacity (DLCO) corrected for hemoglobin \<30% of predicted value. * Severe chronic obstructive bronchitis as characterized by forced expiratory volume in 1 second /forced vital capacity (FEV1/FVC) \<0.70. * Need for 24 hours of oxygen therapy or oxygen saturation \<88% after 10 minutes breathing ambient air at rest. * Known diagnosis of significant respiratory disorders other than IPF. * Pulmonary artery hypertension requiring a specific treatment. * Currently listed and/or anticipated for lung transplantation within the next 6 months (on an active list). * History of vasculitis or connective tissue disorders. * Known human immunodeficiency virus or chronic viral hepatitis. * Participants with active tuberculosis or incompletely treated latent tuberculosis infection. * Use of any cytotoxic/immunosuppressive agent including but not limited to azathioprine, cyclophosphamide, methotrexate, and cyclosporine within 4 weeks prior to screening. * Use of any cytokine modulators (etanercept, adalimumab, efalizumab, infliximab, golimumab, certolizumab, rituximab) within 12 weeks or 5 half-lives of screening (24 weeks for rituximab and 24 months for alefacept). * Use of any investigational drug within 1 month of screening, or 5 half-lives, if known ( whichever was longer), or within 12 weeks for stem cell therapy. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.